Discover and read the best of Twitter Threads about #Galvus
Most recents (1)
#Thread: As @Novartis’ vildagliptin (#Galvus) goes off-patent in #India today and a scramble is expected, some tidbits about this hugely successful drug.
-Vildagliptin, from a class of drugs called DPP-4, was launched in India in 2008 with a licensing arrangement with USV (1)
-Vildagliptin, from a class of drugs called DPP-4, was launched in India in 2008 with a licensing arrangement with USV (1)
-This was one of the first few drugs launched post-2005, the starting of India's product patent era
-Novartis’ drug is Galvus and USV took the brand name Jalra; Novartis marketed Galvus in top cities while USV sold in smaller cities as Jalra (2)
-Novartis’ drug is Galvus and USV took the brand name Jalra; Novartis marketed Galvus in top cities while USV sold in smaller cities as Jalra (2)
-There was ample space for new anti-diabetes therapies and move the market beyond metformin and sulphonyureas
-GSK had a setback after Avandia (thiazolidenediones or TZD) was found to have safety issues. Curiously, a few years later, the drug was cleared by the US FDA (3)
-GSK had a setback after Avandia (thiazolidenediones or TZD) was found to have safety issues. Curiously, a few years later, the drug was cleared by the US FDA (3)
